Cholesterol and cognition in schizophrenia: A double-blind study of patients randomized to clozapine, olanzapine and haloperidol

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 27-33

  Krakowski, Menahem ^a,b   Czobor, Pal ^a,c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Cholesterol; Clozapine; Cognition; Haloperidol; Olanzapine

Indexed keywords

CHOLESTEROL; CLOZAPINE; HALOPERIDOL; OLANZAPINE;

ADULT; ANTICHOLINERGIC SYNDROME; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VERBAL MEMORY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CLOZAPINE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRIGLYCERIDES; YOUNG ADULT;

EID: 79960312024     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.04.005     Document Type: Article

References (42)

1. Benton D. Dietary fat and cognitive functioning. Lipids, Health, and Behavior 1997, 227-243. American Psychological Association, Washington, DC. M. Hillbrand, R.T. Spitz (Eds.).
2. Bianchetti G., Morselli P.L. Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection. Journal of Chromatography 1978, 153:203-209.
3. Bjorkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:1-11.
4. Burger K., Gimpl G., Fahrenholz F. Regulation of receptor function by cholesterol. Cellular and Molecular Life Sciences 2000, 57:1577-1592.
5. Catlow J.T., Barton R.D., Clemens M., Gillespie T.A., Goodwin M., Swanson S.P. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B, Biomedical Applications 1995, 668:85-90.
6. Chino B., Mizuno M., Nemoto T., Yamashita C., Kashima H. Relation between social functioning and neurocognitive test results using the optional thinking test in schizophrenia. Psychiatry and Clinical Neurosciences 2006, 60:63-69.
7. Chouinard G., Ross-Chouinard A., Annable L., Jones B.D. Extrapyramidal symptom rating scale. The Canadian Journal of Neurological Sciences 1980, 7:233.
8. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Assoc. Publishers, Hillsdale NJ. 2nd edition.
9. Compagnone N.A., Mellon S.H. Neurosteroids: biosynthesis and function of these novel neuromodulators. Frontiers in Neuroendocrinology 2000, 21:1-56.
10. Dufour F., Liu Q., Gusev P., Alkon D., Atzori M. Cholesterol-enriched diet affects spatial learning and synaptic function in hippocampal synapses. Brain Research 2006, 1103:88-98.
11. Elias P.K., Elias M.F., D'Agostino R.B., Sullivan L.M., Wolf P.A. Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosomatic Medicine 2005, 67:24-30.
12. Endo Y., Nishimura J.I., Kimura F. Impairment of maze learning in rats following long-term glucocorticoid treatments. Neuroscience Letters 1996, 203:199-202.
13. Engelberg H. Low serum cholesterol and suicide. Lancet 1992, 339:727-729.
14. Farr S.A., Banks W.A., Morley J.E. Effects of leptin on memory processing. Peptides 2006, 27:1420-1425.
15. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
16. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. The American Journal of Psychiatry 1996, 153:321-330.
17. Harvey P.D., Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. The American Journal of Psychiatry 2001, 158:176-184.
18. Harvey P.D., Moriarty P.J., Serper M.R. Practice-related improvements in information processing with novel antipsychotic treatment. Schizophrenia Research 2000, 46:139-148.
19. Heverin M., Meaney S., Lutjohann D., Diczfalusy U., Wahren J., Bjorkhem I. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. Journal of Lipid Research 2005, 46:1047-1052.
20. Hibbeln J.R., Umhau J.C., George D.T., Shoaf S.E., Linnoila M., Salem N. Plasma total cholesterol do not predict CSF neurotransmitter metabolites. The American Journal of Clinical Nutrition 2000, 71(S):331S-338S.
21. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994, 13:195-207.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
23. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 2002, 58:1-10.
24. Krakowski M.I., Czobor P., Citrome L., Bark N., Cooper T.B. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2006, 63:622-629.
25. Krakowski M.I., Czobor P., Nolan K. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Journal of Clinical Psychopharmacology 2008, 28:485-493.
26. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kühn M., Uhr M., Pollmächer T. Body weight and leptin plasma levels during treatment with atypical antipsychotic drugs. The American Journal of Psychiatry 1999, 156:312-314.
27. Li X.L., Aou S., Oomura Y., Hori N., Fukunaga K., Hori T. Impairment of long term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
28. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. The American Journal of Psychiatry 2004, 161:116-124.
29. Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B. Effects of lovastatin on cognitive function and psychological well-being. The American Journal of Medicine 2000, 108:538-546.
30. Muldoon M.F., Flory J.D., Ryan C. Serum cholesterol, the brain, and cognitive functioning. Neuropsychology of Cardiovascular Disease 2001, 37-59. Mahwah, NJ. S.R. Waldstein, M.F. Elias (Eds.).
31. O'Brien W.T., Xu G., Batta A., Tint G.S., Salen G., Dyer C.A., Kendler A., Servatius R.J. Developmental sensitivity of associative learning to cholesterol synthesis inhibitors. Behavioural Brain Research 2002, 129:141-152.
32. Schoknecht P.A., Ebner S., Pond W.G., Zhang S., McWhinney V., Wong W.W., Klein P.D., Dudley M., Goddard-Finegold J., Mersmann H.J. Dietary cholesterol supplementation improves growth and behavioral response of pigs selected for genetically high and low serum cholesterol. The Journal of Nutrition 1994, 124:305-314.
33. Schreurs B.G., Smith-Bell C.A., Darwish D.S., Wang D., Burhans L.B., Gonzales-Joekes J., Deci S., Stankovic G., Sparks D.L. Cholesterol enhances classical conditioning of the rabbit heart rate response. Behavioural Brain Research 2007, 181:52-63.
34. Simpson G.M., Cooper T.A. Clozapine plasma levels and convulsions. The American Journal of Psychiatry 1978, 135:99-100.
35. Skosnik P.D., Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2003, 69:367-384.
36. Sparks D.L., Schreurs B.G. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proceedings of the National Academy of Sciences of theUnited States of America 2003, 100:11065-11069.
37. Sparks D.L., Liu H., Gross D.R., Scheff S.W. Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neuroscience Letters 1995, 187:142-144.
38. Tall A.R., Costet P., Wang N. Regulation and mechanisms of macrophage cholesterol efflux. The Journal of Clinical Investigation 2002, 110:899-904.
39. Voikar V., Rauvala H., Ikonen E. Cognitive deficit and development of motor impairment in a mouse model of Niemann-Pick type C disease. Behavioural Brain Research 2002, 132:1-10.
40. Wardle J., Rogers P., Judd P., Taylor M.A., Rapoport L., Green M., Nicholson P.K. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. The American Journal of Medicine 2000, 108:547-553.
41. Yao J.K. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. Phospholipid Spectrum Disorders in Psychiatry and Neurology 2003, 193-212. Marius Press, Lancashire, UK. 2nd edition. M. Peet, I. Glen, D.F. Horrobin (Eds.).
42. Zhang J., Muldoon M.F., McKeown R.E. Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988-1994. The American Journal of Clinical Nutrition 2004, 80:291-298.